ACEs, SIRT1, and Premature Vascular Aging in Humans
Launched by NATHANIEL JENKINS · Jul 9, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how stressful experiences during childhood, called adverse childhood experiences (ACEs), might cause the blood vessels to age faster and work less well in young adults. The researchers are especially interested in a protein called SIRT1, which helps keep blood vessels healthy. They want to find out if people who had 4 or more ACEs have lower levels of SIRT1 and poorer blood vessel function compared to those with no ACEs. The study will also test if taking a supplement called nicotinamide riboside (NR), which can boost SIRT1 activity, helps improve blood vessel health in those with many ACEs.
To take part, you need to be between 18 and 30 years old and either have no ACEs or have experienced 4 or more ACEs. People with high blood pressure, certain diseases, recent major weight changes, or who use certain medications or substances won’t be eligible. Participants will undergo tests to measure blood vessel function and inflammation. Some will take the NR supplement for 4 weeks to see if it helps improve their blood vessels. This study could help us better understand how early life stress affects heart health and whether certain supplements might reduce those effects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 - 30 years
- • ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2)
- Exclusion Criteria:
- • Resting arterial blood pressure \>140/90 mmHg
- • BMI ≥30 kg/m2 and/or weight unstable (\>2.27 kg change) last 6 month
- • Cardiovascular, metabolic, or pulmonary disease
- • Cardiovascular or metabolic prescription drug use
- • Vasoactive antidepressant drug use (SSRIs and clonidine)
- • Currently pregnant or breastfeeding
- • Heavy alcohol consumption (AUDIT screening)
- • Use of illicit drugs
- • Current tobacco use
- • Regular vigorous (\>6 MET s) aerobic exercise (\>4 bouts/week, \>30 min/bout)
- • Dietary supplementation with antioxidants or habitual use of NSAIDs
About Nathaniel Jenkins
Nathaniel Jenkins is a dedicated clinical trial sponsor with a robust commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Mr. Jenkins leads initiatives that prioritize safety, efficacy, and ethical standards in clinical trials. His expertise in trial design and regulatory compliance ensures that studies are conducted with the highest level of integrity and scientific rigor. Through collaboration with healthcare professionals and research institutions, Nathaniel Jenkins aims to facilitate the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported